Evidence map›Paper›PMID 33380880›Full record

ReviewCurrent oncology (Toronto, Ont.)2020

Bruton tyrosine kinase inhibitors for the frontline treatment of chronic lymphocytic leukemia.

V Banerji, A Aw, S Robinson, S Doucette, A Christofides, L H Sehn

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current oncology (Toronto, Ont.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. [Analysis of infection in B-cell lymphoma patients treated with BTK inhibitors].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023
    Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 1 country.

V BanerjiDepartments of Internal Medicine and Biochemistry and Medical Genetics, Max Rady College of Medicine, Rady Faculty of Health Science, University of Manitoba and Research Institute of Oncology and Hematology at CancerCare Manitoba, Winnipeg, MB.
A AwOttawa Blood Disease Centre, University of Ottawa, Ottawa, ON.
S RobinsonDivision of Hematology, Dalhousie University, Halifax, NS.
S Doucetteimpact Medicom Inc., Toronto, ON.
A Christofidesimpact Medicom Inc., Toronto, ON.
L H SehnBC Cancer-Centre for Lymphoid Cancer, and University of British Columbia, Vancouver, BC.
CancerCare Manitoba · CADalhousie University · CAFluidigm (Canada) · CAImpact · CASpinal Cord Injury BC · CAUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic lymphocytic leukemia (cll) is the most commonly diagnosed adult leukemia in Canada. Biologic heterogeneity of cll between patients results in variable disease trajectories and responses to therapy. Notably, compared with patients lacking high-risk features, those with such features-such as deletions in chromosome 17p, aberrations in the

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellAgammaglobulinaemia Tyrosine KinaseCanadaHumansImmunotherapyProtein Kinase InhibitorsAgammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsBruton tyrosine kinase inhibitorschronic lymphocytic leukemiafirst-line therapyfrontline therapyuntreated disease

Identifiers

PMID33380880
PMCPMC7755444
OpenAlexW3116445431

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.